SCHEMBL1363260

SCHEMBL1363260

Cc1ccccc1OCCCCc1oc(-n2ccnc2C)nc1-c1ccc(F)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
MAPK1 P28482 2/20 0.38
MAPT P10636 5/20 0.36
SMN1; SMN2 Q16637 4/20 0.36
TSHR P16473 3/20 0.36
HSD17B10 Q99714 2/20 0.36
HTT P42858 2/20 0.36
RECQL P46063 1/20 0.36
ALDH1A1 P00352 1/20 0.35
POLB P06746 1/20 0.34
TP53 P04637 2/20 0.33
STAT3 P40763 1/20 0.33
THRB P10828 1/20 0.33
NAMPT P43490 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1362923 0.91 MAPT (0.42) LMNAMEN1KMT2AMAPK1MAPT
SCHEMBL1360022 0.91 MAPT (0.42) LMNAMEN1KMT2AMAPK1MAPT
SCHEMBL1360218 0.91 ALDH1A1 (0.40) LMNAMEN1KMT2AMAPK1MAPT
SCHEMBL1362546 0.91 MAPT (0.42) LMNAMEN1KMT2AMAPK1MAPT
SCHEMBL203742 0.89 TP53 (0.41) LMNAMEN1KMT2AMAPK1MAPT
SCHEMBL1363251 0.88 CETP (0.35) LMNAMEN1KMT2AMAPK1MAPT
Hydrochloric Acid SCHEMBL1362475 0.88 TP53 (0.41) LMNAMEN1KMT2AMAPK1MAPT
SCHEMBL1361008 0.84 PTGS1 (0.34) LMNAMEN1KMT2AMAPK1MAPT
SCHEMBL1363280 0.84 NAMPT (0.37) LMNAMEN1KMT2AMAPK1ALDH1A1
SCHEMBL1361965 0.83 TDP1 (0.35) LMNAMAPTSMN1; SMN2HTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067453-B2 Oxazole compound to treat or prevent diabetic neuropathy; 4-(4-chlorophenyl)-5-(3-(2-methoxyphenoxy)propyl-2-methyl-1-imidazolyl)oxazole TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-11-29 US disclosed
US-20080269219-A1 Neurotrophin production/secretion promoting agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-10-30 US disclosed
US-7396848-B1 oxazole derivatives to treat diabetic neuropathy and/or other kinds of peripheral neuropathy; 4-(4-chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]-2-(2-methyl-1-imidazolyl)oxazole TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-08 US disclosed
EP-1206472-B1 OXAZOLE AND THIAZOLE DERIVATIVES AS NEUROTROPHIN PRODUCTION/SECRETION PROMOTING AGENT TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2003-10-01 EP disclosed
US-6605629-B1 Oxazole derivatives; low toxicity TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269219-A1 Neurotrophin production/secretion promoting agent BDNF, NGF, NTRK2 LMNA 4637/4885MEN1 1544/4885KMT2A 4383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.